We are excited to announce that Eagle IP will be returning as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Spring conference in Boston. Our President and Managing Director, Ms. Jennifer Che, is one of the distinguished speakers at the event. Organized by Life Sciences Intellectual Property Review, this event will take place on May 6-7, 2025, at the Hyatt Regency Boston located at One Avenue de Lafayette, Boston, MA 02111.

Come join us there and meet us at our booth!

Every year, LSPN brings together experts from pharmaceutical, biotech, and medtech industries to discuss innovation and IP protections. The conference covers patentability, eligibility, prosecution, and litigation, offering insights for the entire patent protection lifecycle in the US.

For more information about the conference and to complete your registration, please visit: https://www.lspnnorthamerica.com

If you won’t be able to attend LSPN but will be in Boston and would like to schedule a meeting, please let us know. We would be happy to arrange a convenient time to connect.

We are looking forward to seeing you in Boston!

我們過去活動

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by Managing IP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

2025年6月11日

Insights from HKSTP Market Discovery - BIO Connect

2025年5月28日

HKMHDIA Medical Fair Forum

2025年5月27日

Celebrating Innovation at the Asia Summit for Global Health

2025年5月26日

Recommended Insights

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]
閱讀更多 >

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

2021年4月28日
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]
閱讀更多 >

Foreigners Beware: China Proposes Requiring IP Made Using Exported Chinese Genetic Resources to be Co-Owned by Chinese Collaborators

2023年3月22日
Proposed Examination Guidelines for the New Chinese Patent Law – Topic 2: Genetic Resource Restriction How Will the Tightened Genetic Resource Restrictions Affect Your IP In 2019-2021, China’s Ministry of Science and Technology (“MOST”, or the Science Ministry) established several laws and regulations with respect to biosafety1 and human genetic resources management2 (collectively referred as […]
閱讀更多 >

China Top 50 Case of 2019: How a Functional Feature is Construed Greatly Impacts Protection Scope - Shimano KK v. SENSAH

2020年7月20日
Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]
閱讀更多 >
Top crossarrow-right